Article Text

other Versions

PDF
Extended report
Activated LTB4 pathway in muscle tissue of patients with polymyositis or dermatomyositis
  1. Ingela Loell1,
  2. Li Alemo Munters1,
  3. Jayesh Pandya1,
  4. Mei Zong1,
  5. Helene Alexanderson1,2,
  6. Andreas E Fasth1,
  7. Christina Ståhl Hallengren3,
  8. Olof Rådmark4,
  9. Ingrid E Lundberg1,
  10. Per-Johan Jakobsson1,
  11. Marina Korotkova1
  1. 1Rheumatology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Solna, Stockholm, Sweden
  2. 2Department of Physical Therapy, Orthopaedic/Rheumatology Unit, Karolinska Univeristy Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
  3. 3Rheumatology Unit, Helsingborgs Lasarett, Helsingborg, Sweden
  4. 4Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
  1. Correspondence to Dr Ingela Loell, Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm SE-171 76, Sweden; Ingela.Loell{at}ki.se

Objective

To investigate the involvement of the leukotriene B4 (LTB4) pathway in polymyositis (PM) and dermatomyositis (DM) and the effect of immunosuppressive treatment on the LTB4 pathway.

Methods 5-lipoxygenase (5-LO), 5-LO activating protein (FLAP) and LTB4 receptor-1 (BLT1) expression was analysed by immunohistochemistry in muscle tissue from patients with PM/DM before and after immunosuppressive treatment and from healthy individuals. In vivo LTB4 in thigh muscle was measured by microdialysis at rest and after acute exercise in another cohort of patients and healthy controls.

Results The number of 5-LO-positive cells and BLT1-positive capillaries was higher in patients with PM/DM than in healthy individuals. The number of FLAP-expressing cells divided the patients into two groups (high/low expression). Treatment reduced the number of FLAP-positive cells in the group with initial high levels, however the expression remained high compared with healthy individuals. The number of BLT1-positive cells was also reduced while staining for 5-LO was unchanged. An inverse correlation was observed between the number of 5-LO or FLAP-positive cells in muscle tissue and muscle performance. LTB4 could be detected in dialysate of muscle tissue in vivo in both patients and healthy controls and was significantly increased after exercise in patients.

Conclusion The LTB4 pathway is upregulated in muscle tissue from patients with PM/DM and this upregulation correlated negatively to muscle performance, suggesting a role for LTB4 in myositis muscle weakness. The immunosuppressive treatment was insufficient on the LTB4 pathway and, for patients with high expression of FLAP, FLAP inhibitors may be considered as possible therapy.

Statistics from Altmetric.com

Footnotes

  • Funding Supported by grants from The Swedish Medical Research Council, The Myositis Association, the Swedish Rheumatism Association, King Gustaf V 80 year Foundation, the European Union Sixth Framework Programme (project AutoCure; LSH-018661), and Karolinska Institutet Foundation, Marianne and Marcus Wallenberg Foundation, the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and the Karolinska Institutet, Promobilia and the Association Francaise contres les Myopathies.

  • Competing interest None.

  • Patient consent Obtained.

  • Ethics approval The local ethics committee at Karolinska University Hospital.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.